Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Ropivacaine

Generic Name: Ropivacaine

Brand Names: Naropin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₆N_₂O

CAS Number: 84057-95-4

Unique Ingredient Identifier: 7IO5LYA57N

Overview

Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.

Background

Indication

Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.

Associated Conditions

Acute Pain
Postoperative pain

Clinical Trials

Addition of Dexmedetomidine to Ropivacaine in Bilateral Erector Spinae Plane Block in Patients Undergoing Coronary Artery Bypass Surgery

Phase 4

Not yet recruiting

Posted: 2025/05/21

Sponsor:Lebanese American Un...

ID:NCT06981949

Combined Local Anesthetic Blockade and Neuromodulation vs Local Anesthetic Blockade Only for Analgesia After Below-knee Amputation: RCT

Not Applicable

Not yet recruiting

Posted: 2025/05/09

Sponsor:Stanford University

ID:NCT06964347

Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome

Not Applicable

Not yet recruiting

Posted: 2025/05/01

Sponsor:Stanford University

ID:NCT06953661

Influence of Standardized Perioperative Anesthetic, Analgesic Care on Outcome of Patients Undergoing Hip Fracture Surgeries

Phase 1

Not yet recruiting

Posted: 2025/04/13

Sponsor:Milton S. Hershey Me...

ID:NCT06925789

Efficacy and Safety of Cocktail of Ropivacaine for Local Infiltration Analgesia in Patients Undergoing Laparoscopic Cholecystectomy

Not Applicable

Recruiting

Posted: 2025/02/11

Sponsor:

Sichuan Provincial P...

ID:NCT06819748

FDA Approved Products

Ropivacaine Hydrochloride

Manufacturer:Hospira, Inc.

Route:INFILTRATION, EPIDURAL, PERINEURAL

Strength:2 mg in 1 mL

Approved: 2024/03/04

NDC:0409-9300

ROPIVACAINE HYDROCHLORIDE

Manufacturer:Baxter Healthcare Corporation

Route:EPIDURAL, INFILTRATION, PERINEURAL

Strength:10 mg in 1 mL

Approved: 2020/04/09

NDC:43066-027

Ropivacaine Hydrochloride

Manufacturer:NorthStar Rx LLC

Route:EPIDURAL, INFILTRATION, PERINEURAL

Strength:5 mg in 1 mL

Approved: 2024/03/01

NDC:72603-218

Ropivacaine Hydrochloride

Manufacturer:Eugia US LLC

Route:PERINEURAL, EPIDURAL

Strength:7.5 mg in 1 mL

Approved: 2023/05/20

NDC:55150-199

ROPIVACAINE HYDROCHLORIDE

Manufacturer:Baxter Healthcare Corporation

Route:EPIDURAL, INFILTRATION, PERINEURAL

Strength:5 mg in 1 mL

Approved: 2020/04/09

NDC:43066-023

Singapore Approved Products

ROPIVACAINE-AFT SOLUTION FOR INJECTION 1% W/V

Manufacturer:Elpen Pharmaceutical Co., Inc

Form:INJECTION, SOLUTION

Strength:10 mg/mL

Online:Yes

Approved: 2017/06/08

Approval:SIN15261P

ROPIVACAINE-AFT SOLUTION FOR INFUSION 0.2% W/V

Manufacturer:Elpen Pharmaceutical Co., Inc

Form:INFUSION, SOLUTION

Strength:2.0 mg/mL

Online:Yes

Approved: 2017/06/08

Approval:SIN15264P

NAROPIN INFUSION 0.2%

Manufacturer:ASTRAZENECA PTY LTD

Form:INJECTION

Strength:2 mg/ml

Online:Yes

Approved: 1997/03/26

Approval:SIN09262P

ROPIVACAINE-AFT SOLUTION FOR INJECTION 0.2% W/V

Manufacturer:Elpen Pharmaceutical Co., Inc

Form:INJECTION, SOLUTION

Strength:2.0 mg/mL

Online:Yes

Approved: 2017/06/08

Approval:SIN15263P

ROPIVACAINE-AFT SOLUTION FOR INJECTION 0.75% W/V

Manufacturer:Elpen Pharmaceutical Co., Inc

Form:INJECTION, SOLUTION

Strength:7.5 mg/mL

Online:Yes

Approved: 2017/06/08

Approval:SIN15262P

Related News

PainReform's PRF-110 Phase 3 Trial Fails to Meet Primary Endpoint in Post-Surgical Pain Management

5 months ago

PainReform's Phase 3 clinical trial of PRF-110 for post-surgical pain management in bunionectomy patients did not meet its primary endpoint.

PainReform's PRF-110 Shows Early Post-Surgical Pain Reduction in Phase 3 Trial

6 months ago

PainReform's PRF-110 demonstrated statistically significant superiority over placebo in reducing pain within the first 48 hours post-bunionectomy, according to initial Phase 3 data.

PainReform's PRF-110 Shows Promise in Phase 3 Bunionectomy Trial, Data Incoherence Hinders Full Analysis

6 months ago

PainReform's PRF-110 demonstrated statistically significant pain reduction compared to placebo in the first 48 hours post-bunionectomy, suggesting effective early postoperative pain relief.

Erector Spinae Plane Block vs. Serratus Anterior Plane Block for Post-LSG Analgesia: A Randomized Trial

8 months ago

A randomized clinical trial is underway to compare the efficacy of Erector Spinae Plane Block (ESB) versus Serratus Anterior Plane Block (SAPB) for pain management after Laparoscopic Sleeve Gastrectomy (LSG).

PainReform's PRF-110 Shows Compatibility with Surgical Sutures in Clinical Trials

9 months ago

PainReform's PRF-110, a non-opioid post-surgical pain relief solution, demonstrates compatibility with both non-absorbable and resorbable sutures in human clinical trials.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy